The Peptidic GHS-R antagonist [D-Lys3]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity

0363114 - ÚOCHB 2012 RIV IE eng J - Journal Article
Maletínská, Lenka - Matyšková, Resha - Maixnerová, Jana - Sýkora, D. - Pýchová, Miroslava - Špolcová, Andrea - Blechová, Miroslava - Drápalová, J. - Lacinová, Z. - Haluzík, M. - Železná, Blanka
The Peptidic GHS-R antagonist [D-Lys3]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity.
Molecular and Cellular Endocrinology. Roč. 343, 1/2 (2011), s. 55-62. ISSN 0303-7207. E-ISSN 1872-8057
R&D Projects: GA ČR GA303/09/0744
Institutional research plan: CEZ:AV0Z40550506
Keywords : GHS-R * [D-Lys3]GHRP-6 * ovariectomized obese mice
Subject RIV: CE - Biochemistry
Impact factor: 4.192, year: 2011

Ghrelin receptor antagonist [D-Lys3]GHRP-6 after seven days of subcutaneous treatment markedly decreased food intake in OVX mice fed both HF and standard diets; furthermore, it reduced body weight and blood glucose, insulin and leptin, and increased beta-hydroxybutyrate level and uncoupling-protein-1 mRNA in brown adipose tissue. Pair-feeding revealed that effect of [D-Lys3]GHRP-6 was primary anorexigenic. Estrogen supplementation reduced anorexigenic effects of [D-Lys3]GHRP-6. OVX [D-Lys3]GHRP-6 treatment in mice on HF diet resulted in markedly increased circulating level and liver expression of a major metabolic regulator, fibroblast growth factor 21. Our data suggest that ghrelin antagonists could be especially beneficial in individuals with common obesity combined with estrogen deficiency.
Permanent Link: http://hdl.handle.net/11104/0199190